Stifel lowered the firm’s price target on Elanco (ELAN) to $18 from $20 and keeps a Buy rating on the shares. The firm’s thesis remains that in 2026 and beyond, EBITDA growth will outstrip revenue growth and EPS will grow faster than EBITDA, telling investors that Elanco “offers the best risk/reward among our Animal Health names.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELAN:
- Elanco initiated with a Buy at UBS
- Elanco initiated with a Market Perform at Leerink
- Class Action Lawsuit Against Elanco Animal Health Inc. (NYSE:ELAN)
- Elanco acquires contract manufacturing facility in Speke, UK
- Elanco Animal Health Strengthens Board with New Appointment
Questions or Comments about the article? Write to editor@tipranks.com